260 related articles for article (PubMed ID: 9591730)
21. Melan-A (A103) and inhibin expression in ovarian neoplasms.
Yao DX; Soslow RA; Hedvat CV; Leitao M; Baergen RN
Appl Immunohistochem Mol Morphol; 2003 Sep; 11(3):244-9. PubMed ID: 12966351
[TBL] [Abstract][Full Text] [Related]
22. Comparison of immunohistochemical labelling of melanocyte differentiation antibodies melan-A, tyrosinase and HMB 45 with NKIC3 and S100 protein in the evaluation of benign naevi and malignant melanoma.
Orchard GE
Histochem J; 2000 Aug; 32(8):475-81. PubMed ID: 11095072
[TBL] [Abstract][Full Text] [Related]
23. Human monoclonal antibodies that distinguish cutaneous malignant melanomas from benign nevi in fixed tissue sections.
Imam A; Mitchell MS; Modlin RL; Taylor CR; Kempf RA; Kan-Mitchell J
J Invest Dermatol; 1986 Feb; 86(2):145-8. PubMed ID: 3528308
[TBL] [Abstract][Full Text] [Related]
24. Improved immunohistochemical evaluation of micrometastases in sentinel lymph nodes of cutaneous melanoma with 'MCW melanoma cocktail'--a mixture of monoclonal antibodies to MART-1, Melan-A, and tyrosinase.
Shidham VB; Qi D; Rao RN; Acker SM; Chang CC; Kampalath B; Dawson G; Machhi JK; Komorowski RA
BMC Cancer; 2003 May; 3():15. PubMed ID: 12735792
[TBL] [Abstract][Full Text] [Related]
25. Melan A and S100 protein immunohistochemistry in feline melanomas: 48 cases.
Ramos-Vara JA; Miller MA; Johnson GC; Turnquist SE; Kreeger JM; Watson GL
Vet Pathol; 2002 Jan; 39(1):127-32. PubMed ID: 12102204
[TBL] [Abstract][Full Text] [Related]
26. Immunostaining of human melanomas by a monoclonal antibody to B700 mouse melanoma antigen.
Xu X; Azumi N; Skelton HG; Hearing VJ; Gersten DM
Eur J Cancer; 1996 Jan; 32A(1):168-73. PubMed ID: 8695227
[TBL] [Abstract][Full Text] [Related]
27. Immunohistochemical double stains against Ki67/MART1 and HMB45/MITF: promising diagnostic tools in melanocytic lesions.
Nielsen PS; Riber-Hansen R; Steiniche T
Am J Dermatopathol; 2011 Jun; 33(4):361-70. PubMed ID: 21610457
[TBL] [Abstract][Full Text] [Related]
28. Nuclear to non-nuclear Pmel17/gp100 expression (HMB45 staining) as a discriminator between benign and malignant melanocytic lesions.
Rothberg BE; Moeder CB; Kluger H; Halaban R; Elder DE; Murphy GF; Lazar A; Prieto V; Duncan LM; Rimm DL
Mod Pathol; 2008 Sep; 21(9):1121-9. PubMed ID: 18552823
[TBL] [Abstract][Full Text] [Related]
29. Melan-A/MART-1 antigen expression in cutaneous and ocular melanomas.
Nicotra MR; Nisticò P; Mangoni A; Di Filippo F; Marincola FM; Natali PG
J Immunother; 1997 Nov; 20(6):466-9. PubMed ID: 9409452
[TBL] [Abstract][Full Text] [Related]
30. A comparative immunohistochemical study of MART-1 expression in Spitz nevi, ordinary melanocytic nevi, and malignant melanomas.
Bergman R; Azzam H; Sprecher E; Manov L; Munichor M; Friedman-Birnbaum R; Ben-Itzhak O
J Am Acad Dermatol; 2000 Mar; 42(3):496-500. PubMed ID: 10688724
[TBL] [Abstract][Full Text] [Related]
31. Melan-A, a new melanocytic differentiation marker.
Busam KJ; Jungbluth AA
Adv Anat Pathol; 1999 Jan; 6(1):12-8. PubMed ID: 10197235
[TBL] [Abstract][Full Text] [Related]
32. Melanoma-associated antigen recognized by T cells (MART-1): the advent of a preferred immunocytochemical antibody for the diagnosis of metastatic malignant melanoma with fine-needle aspiration.
Fetsch PA; Marincola FM; Filie A; Hijazi YM; Kleiner DE; Abati A
Cancer; 1999 Feb; 87(1):37-42. PubMed ID: 10096358
[TBL] [Abstract][Full Text] [Related]
33. Serological analysis of Melan-A(MART-1), a melanocyte-specific protein homogeneously expressed in human melanomas.
Chen YT; Stockert E; Jungbluth A; Tsang S; Coplan KA; Scanlan MJ; Old LJ
Proc Natl Acad Sci U S A; 1996 Jun; 93(12):5915-9. PubMed ID: 8650193
[TBL] [Abstract][Full Text] [Related]
34. Expression of melanocyte-associated markers gp-100 and Melan-A/MART-1 in angiomyolipomas. An immunohistochemical and rt-PCR analysis.
Jungbluth AA; Iversen K; Coplan K; Williamson B; Chen YT; Stockert E; Old LJ; Busam KJ
Virchows Arch; 1999 May; 434(5):429-35. PubMed ID: 10389626
[TBL] [Abstract][Full Text] [Related]
35. The use of immunocytochemical study in the cytologic diagnosis of melanoma: evaluation of three antibodies.
Jing X; Michael CW; Theoharis CG
Diagn Cytopathol; 2013 Feb; 41(2):126-30. PubMed ID: 22021247
[TBL] [Abstract][Full Text] [Related]
36. Expression of Melan-A in Spitz, pigmented spindle cell nevi, and congenital nevi: comparative immunohistochemical study.
Evans MJ; Sanders DS; Grant JH; Blessing K
Pediatr Dev Pathol; 2000; 3(1):36-9. PubMed ID: 10644168
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of micrometastases in sentinel lymph nodes of cutaneous melanoma: higher diagnostic accuracy with Melan-A and MART-1 compared with S-100 protein and HMB-45.
Shidham VB; Qi DY; Acker S; Kampalath B; Chang CC; George V; Komorowski R
Am J Surg Pathol; 2001 Aug; 25(8):1039-46. PubMed ID: 11474288
[TBL] [Abstract][Full Text] [Related]
38. Microphthalmia transcription factor expression in cutaneous benign, malignant melanocytic, and nonmelanocytic tumors.
King R; Googe PB; Weilbaecher KN; Mihm MC; Fisher DE
Am J Surg Pathol; 2001 Jan; 25(1):51-7. PubMed ID: 11145251
[TBL] [Abstract][Full Text] [Related]
39. Diagnostic assessment of two novel proliferation-specific antigens in benign and malignant melanocytic lesions.
Rudolph P; Lappe T; Schubert C; Schmidt D; Parwaresch RM; Christophers E
Am J Pathol; 1995 Dec; 147(6):1615-25. PubMed ID: 7495287
[TBL] [Abstract][Full Text] [Related]
40. Expression of the B-cell proliferation marker MUM1 by melanocytic lesions and comparison with S100, gp100 (HMB45), and MelanA.
Sundram U; Harvell JD; Rouse RV; Natkunam Y
Mod Pathol; 2003 Aug; 16(8):802-10. PubMed ID: 12920225
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
